All relevant data are available from Open Science Framework through the following DOI: [10.17605/OSF.IO/C7TWS](https://doi.org/10.17605/OSF.IO/C7TWS).

Introduction {#sec006}
============

Vitiligo is an acquired chronic depigmenting disorder of the skin, predominantly asymptomatic, manifested by circumscribed depigmented macules and patches due to the disappearance of melanocytes from the epidermis. Vitiligo was recognized in ancient times and is still confused with leprosy in some countries\[[@pone.0210581.ref001]\]. Numerous studies have revealed that vitiligo has a major effect on the patients' quality of life (QoL) and negatively affects sexual relations\[[@pone.0210581.ref002]\].

Cosmetic camouflage is an alternative and complementary option to the traditional standard treatment options, since the effectiveness of the latter are often disappointing with only partial results, and the treatment may last for months or years, before re-pigmentation occur. Preliminary studies have reported that camouflage for patients with vitiligo could improve their quality of life\[[@pone.0210581.ref003],[@pone.0210581.ref004]\]. However, all these studies were conducted in small populations, therefore this effect remains to be observed in a larger population. Furthermore, the effect of camouflage on QoL can be significantly influenced by social-psychological factors but has not been studied in Chinese population.

We conducted this study to determine the dermatology-specific QoL in a group of adult vitiligo patients using camouflage in a large Chinese vitiligo community, especially to identify the possible risk factors for poor QoL. We also used a vitiligo-specific QoL questionnaire to illustrate the vitiligo-specific QoL aspects that haven't been covered by DLQI.

Methods {#sec007}
=======

An online survey was conducted from September to December 2016 to assess QoL of adult vitiligo patients using camouflage, and to identify risk factors that related to poor QoL.

Recruitment {#sec008}
-----------

An online questionnaire was formulated and sent to 8602 consecutive adult patients (age ≥18 years) with vitiligo, in WeChat groups and QQ groups of a vitiligo community, "Leukoplakia Common Home". Before taking the survey, participants had to sign the online consent form first. Patients who had been using camouflage for more than 1 month were invited. Patients who were younger than 18 years, and who had not been diagnosed by dermatologists were excluded from the study. Information that could identify individual participants was not collected.

The study protocol was approved by the ethics committee of Beijing Tsinghua Changgung Hospital.

Measures {#sec009}
--------

### Demographic and clinical Information {#sec010}

Demographic and clinical information was collected including gender, age, residential location, marital status, fertility status, educational level, employment status, income, duration of the disease, localizations of vitiligo (e.g. face, neck, scalp, upper arms, forearms, hands, thighs, legs, feet, chest, upper back, waist, axillae, groins, anogenital area), percentage of body surface area (BSA) affected, symptoms, duration of camouflage therapy, degree of satisfaction in camouflage therapy, other previous treatment, and total cost of treatment, as well as visual analogue scale (VAS) to assess the patient-perceived severity.

### Quality of life {#sec011}

We used a dermatology-specific QoL questionnaire, Dermatology Life Quality Index (DLQI) and a vitiligo-specific QoL questionnaire, Vitiligo Impact Scale-22 (VIS-22), to assess the impact of vitiligo. The DLQI contains 10 questions related to patients' symptoms and feelings, daily activities, leisure, work or school, personal relationships, and treatment over the previous 1 week, and each question has four possible answers scored from 0 to 3. The VIS-22 comprises 22 items covering domains of self-confidence, anxiety, depression, marriage, family worries, social interactions, school/college-related, occupation-related, treatment-related and attitude. Each question has four possible answers scored from 0 to 3. The QoL impairment could be classified into 5 levels according to the total score of DLQI. A DLQI score of 0--1 means no effect at all, 2--5 means a small effect, 6--10 moderate effect, 11--20 large effect, and 21--30 extremely large effect on patient's life.

Statistical analysis {#sec012}
--------------------

The data was carefully checked for consistency and plausibility to guarantee the quality of data. Normally distributed data were expressed as means±SD, whereas variables with a skewed distribution were reported as median (range). Categorical variables were represented by frequency and percentage. Univariate associations were calculated using Mann-Whitney U test or Kruskal-Wallis test with Bonferroni correction. The outcome variables were the sum score of DLQI. Independent variables were the sociodemographic and clinical characteristics. The independent variables that were univariately associated with the outcome variables (P \<0.10) were entered into a stepwise multivariate logistic regression models with dichotomized DLQI (6--30 vs. 0--5) as dependent variable. A value of P \< 0.05 was considered significant. All calculations were performed with the statistical package Stata 12.0 (Stata Corp., College Station, Tex.).

Results {#sec013}
=======

One thousand nine hundred and twenty four patients had shown a willingness to participate in this study. Of whom 1198 completed the questionnaires. However, 314 were excluded after plausibility checking ([Fig 1](#pone.0210581.g001){ref-type="fig"}). Therefore, 884 respondents were included in the final analyses.

![Flow diagram of patient enrollment, exclusion, data quality control and data analysis.\
(Online completion ensured that there were no missing data in completed questionnaires).](pone.0210581.g001){#pone.0210581.g001}

Demographic and clinical characteristics of respondents {#sec014}
-------------------------------------------------------

The median age of these 884 respondents was 36 years (range 18--83); 413 (46.7%) were male. The visible body areas, such as face, scalp, neck, hands, were affected in most of the patients (n = 829, 93.8%). All but one patient had received previous treatment. The median duration of camouflage therapy was 50 months (range 1--216). The demographic and clinical characteristics were presented in [Table 1](#pone.0210581.t001){ref-type="table"}.

10.1371/journal.pone.0210581.t001

###### Demographic and clinical characteristics of the study group.

![](pone.0210581.t001){#pone.0210581.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          Study population (n)\   Percent (%)
                                                                          N = 854                 
  ----------------------------------------------------------------------- ----------------------- ---------------------------------------------------
  Gender                                                                                          

      Male                                                                413                     46.7

      Female                                                              471                     53.3

  Age, y                                                                  38.88 ± 13.10           36 (18--83)[^a^](#t001fn001){ref-type="table-fn"}

      18--29                                                              264                     29.9

      30--49                                                              421                     47.6

      50--69                                                              183                     20.7

      ≥ 70                                                                16                      1.8

  Marital status                                                                                  

      Single, without a committed relationship                            101                     11.4

      Single, in a committed relationship                                 71                      8.0

      Married                                                             686                     77.6

      Divorced                                                            19                      2.2

      Widowed                                                             7                       0.8

  Fertility status                                                                                

      No children                                                         222                     25.1

      Have child/children                                                 662                     74.9

  Residential location                                                                            　

      Urban                                                               754                     85.3

      Rural                                                               130                     14.7

  Educational level                                                                               

      Less than high school                                               132                     14.9

      High school diploma or equivalent                                   274                     31.0

      College graduate                                                    437                     49.4

      Postgraduate                                                        41                      4.6

  Employment status                                                                               

      Employed                                                            662                     74.9

      Unemployed and Seeking Work                                         81                      9.2

      Students                                                            24                      2.7

      Retire                                                              117                     13.2

  Onset age, y                                                            23.41 ± 13.03           21 (1--70)

      \<20                                                                391                     44.2

      20--29                                                              244                     27.6

      30--40                                                              127                     14.4

      ≥ 40                                                                122                     13.8

  Disease duration, y                                                     15.47 ± 10.38           14 (0--55)

      \<5                                                                 119                     13.5

      5--10                                                               153                     17.3

      10--20                                                              358                     40.5

      ≥ 20                                                                254                     28.7

  Number of affected body sites                                           4.87 ± 3.83             4 (1--15)

      Visible body areas affected[^b^](#t001fn002){ref-type="table-fn"}   829                     93.8

  Localization[^c^](#t001fn003){ref-type="table-fn"}                                              

      Face                                                                561                     63.5

      Neck                                                                389                     44.0

      Scalp                                                               194                     22.0

      Upper arms                                                          233                     26.4

      Forearms                                                            246                     27.8

      Hands                                                               604                     68.3

      Thighs                                                              252                     28.5

      Legs                                                                254                     28.7

      Feet                                                                340                     38.5

      Chest                                                               243                     27.5

      Upper back                                                          205                     23.2

      Waist                                                               314                     35.5

      Axillae                                                             170                     19.2

      Groins                                                              134                     15.2

      Anogenital                                                          163                     18.4

  Extension (%BSA)                                                                                

      \<1%                                                                355                     40.2

      1--3%                                                               207                     23.4

      3--10%                                                              162                     18.3

      \>10%                                                               160                     18.1

  Symptoms                                                                                        　

      Pruritus                                                            100                     11.3

      Pain                                                                12                      1.4

      Sunburn                                                             210                     23.8

      Koebner phenomenon                                                  300                     33.9

      Asymptomatic                                                        455                     51.5

  VAS score of severity                                                   4.77 ± 2.79             4.9 (0--10)　

  Total cost of treatment                                                                         

      \<10,000 RMB                                                        278                     31.5

      10,000--50,000 RMB                                                  398                     45.0

      \>50,000--10,000 RMB                                                208                     23.5

  Duration of camouflage therapy, m                                       58.1 ± 44.3             50 (1--216)

  Degree of satisfaction in camouflage use                                                        

      Not at all                                                          18                      2.0

      A little                                                            239                     27.0

      A lot                                                               545                     61.7

      Very much                                                           82                      9.3
  ---------------------------------------------------------------------------------------------------------------------------------------------------

^a^ All quantitative data were presented as mean ± SD, median (range).

^b^ The visible body areas were defined as face, scalp, neck, and hands.

^c^ Multiple-choice questions with more than one answer; the sum of percentage \>100%.

Quality of life {#sec015}
---------------

The DLQI score (mean± SD) was 5.83±5.75 (range 0--30), and 228 (25.8%) patients reported DLQI scores between 0--1, which mean no effect at all; 294 (33.3%) reported small effects; 198 (22.4%), moderate effects; 164 (18.5%), large to extremely large effects. The mean± SD score for the six domains of DLQI were 1.47±1.52 for daily activities, 1.47±1.53 for leisure, 1.25±1.14 for symptoms and feelings, 0.63±1.22 for personal relationship, 0.51±0.88 for work and school, and 0.49±0.79 for treatment. The frequency of the answers to each item of the DLQI and VIS-22 were shown in [Fig 2](#pone.0210581.g002){ref-type="fig"}.

![Frequency of the answers to each item of the DLQI and VIS-22 questionnaires, ordered by mean scores of each item.](pone.0210581.g002){#pone.0210581.g002}

Factors associated with quality of life {#sec016}
---------------------------------------

### Univariate associations {#sec017}

The dermatology-specific QoL was more impaired in female patients with vitiligo, and those who were younger than 30y/o, and who live in rural areas had significantly higher scores on DLQI.

The involvement of any part of the body except for face and upper arms, as well as greater percentages of BSA affected were associated with significantly higher scores of DLQI. Patients with symptoms, such as pruritus, pain, koebner phenomenon, and sunburn, had significantly higher DLQI scores compared with those without.

Marriage, fertility and occupational status, as well as total cost of treatment, and the degree of satisfaction in camouflage therapy also had influences on DLQI ([S1 Table](#pone.0210581.s001){ref-type="supplementary-material"}).

### Multivariate associations {#sec018}

Multivariate logistic regression analysis revealed that gender, age, marriage status, occupational status, anogenital involvement, patient-perceived severity (presented by VAS score), symptoms as itching, pain, sunburn and koebner phenomenon, total cost of treatment and degree of satisfaction in camouflage therapy were statistically independently associated with DLQI score ([Table 2](#pone.0210581.t002){ref-type="table"}).

10.1371/journal.pone.0210581.t002

###### Multivariate logistic regression to identify sociodemographic and clinical factors related to poor health-related quality of life[^a^](#t002fn002){ref-type="table-fn"}.

![](pone.0210581.t002){#pone.0210581.t002g}

                                                                                                 DLQI           
  -------------------------------------------------------------------------------------- ------- -------------- ---------
  Gender (female vs. male)                                                               1.79    1.28\~2.52     0.001
  Age (≥30 vs. \<30 y/o)                                                                 0.45    0.30\~0.66     \<0.001
  Marriage (Single, without a committed relationship vs. married)                        2.38    1.38\~4.11     0.002
  Occupational status (Employed vs. retire)                                              1.70    1.03\~2.81     0.038
  Occupational status (Unemployed and Seeking Work vs. retire)                           2.11    1.04\~4.29     0.038
  Anogenital involvement                                                                 1.92    1.22\~3.01     0.004
  Hands involvement                                                                      1.47    1.00\~2.16     0.052
  Itching                                                                                2.54    1.51\~4.29     \<0.001
  Pain                                                                                   12.76   1.25\~130.71   0.032
  Sunburn                                                                                2.80    1.90\~4.13     \<0.001
  Koebner phenomenon                                                                     1.83    1.29\~2.59     0.001
  VAS score of severity                                                                  1.20    1.13\~1.28     \<0.001
  Cost of treatment (≥10,000 vs. \<10,000 RMB)                                           1.48    1.02\~2.14     0.037
  Degree of satisfaction in camouflage use (Very much/ A lot vs. A little/ not at all)   0.49    0.34\~0.70     \<0.001

Abbreviations: OR, Odds ratio; CI, Confidence interval

^a^ A poor QoL was defined as DLQI scores between 6--30. The logistic regression model fit was tested with the likelihood ratio test (P\<0.0001).

Discussion {#sec019}
==========

Impact of QoL of vitiligo and the assessment tools {#sec020}
--------------------------------------------------

Vitiligo is often perceived as a cosmetic disease, whereas it has a profound and permanent impact on patients' quality of life (QoL). Numerous studies had revealed the association of stigmatization, distress, depression, anxiety, low self-esteem, social isolation and impact on sexual life with vitiligo\[[@pone.0210581.ref005],[@pone.0210581.ref006]\]. DLQI is one of the most widely used dermatology-specific QoL instruments in vitiligo, and the DLQI scores reported by previous studies showed obvious geographical differences, with the highest mean DLQI score of 15.00 reported in a Turkish study\[[@pone.0210581.ref007]\], followed by two Arab studies (mean score 11.86) \[[@pone.0210581.ref008],[@pone.0210581.ref009]\], and ten Indian studies (mean score 9.51)\[[@pone.0210581.ref010]--[@pone.0210581.ref016]\], while the lowest score was 1.82 in one Italian study\[[@pone.0210581.ref017],[@pone.0210581.ref018]\]. Therefore, QoL of vitiligo patients is considerably variable according to different skin phototypes and cultures. However, few studies have reported the impact of vitiligo on Chinese patients' QoL. Although preliminary studies have shown that camouflage can help improving QoL of the patients\[[@pone.0210581.ref003],[@pone.0210581.ref004]\], this have never been studied in Chinese patients.

This is the first study to evaluate the impact of vitiligo on Chinese patients who had been using camouflage. To obtain a more comprehensive profile of QoL, we conducted the study in a large vitiligo community using both dermatology-specific and vitiligo-specific QoL instruments.

Since disease-specific instruments could be more sensitive to disease-specific issues, there were four vitiligo-specific Qol instruments had been developed in recent years, including Vitiligo-specific Quality-of-Life instrument (VitiQoL) in the U.S.\[[@pone.0210581.ref019]\], Vitiligo Impact Patient Scale (VIPs) in France\[[@pone.0210581.ref020]\], Vitiligo Life Quality Index (VLQI) in Turkey\[[@pone.0210581.ref007]\], and Vitiligo Impact Scale-22 (VIS-22) in India\[[@pone.0210581.ref013]\]; and since China and India shared many similarities in culture and belief, we chose the VIS-22 to estimate the vitiligo-specific Qol in our participants. Compared with DLQI, VIS-22 covered the attitude and anxiety about the disease, as well as family worries. Nevertheless, VIS-22 did not have any questions concerned about the symptoms and sexual life.

Impairment of QoL found in Chinese vitiligo patients {#sec021}
----------------------------------------------------

Eight hundred and eighty four vitiligo patients who had been using camouflage for more than 1 month were available for final analyses. The mean total score of DLQI was 5.83. There were more than one third of the vitiligo patients experiencing a significant impairment of QoL, as 40.9% of the patients reported a moderate to extremely large QoL impairment assessed with DLQI (score 6--30).

The highest DLQI score was found in 'daily activities', followed by 'leisure' and 'symptoms and feelings'. The high scores of VIS-22 added more detailed information of QoL in domains of attitude and anxiety about the disease, such as 'disease incurable', 'worried about new lesions', 'the worst disease', and 'keep thinking about this disease'; and treatment-related burdens, such as 'difficulties in adhering to treatment', 'the amount of money spent on treatment'; then 'problems in getting married' and the feelings of 'embarrassment' and 'helpless', while there were only small impacts on work/school life or personal relationship.

Risk factors related to QoL {#sec022}
---------------------------

The impact of vitiligo on QoL varies in patients with different clinical and demographic characteristics. In the majority of previous studies, women showed more QoL impairment than men did\[[@pone.0210581.ref018]\], as did young patients compared to elderly ones\[[@pone.0210581.ref010]\], married women with vitiligo than singles\[[@pone.0210581.ref021]\], and patients with involvement on exposed sites than those on unexposed sites\[[@pone.0210581.ref018],[@pone.0210581.ref022]--[@pone.0210581.ref024]\]. Our results showed that female patients, patients aged less than 30 y/o, patients who were single and without a committed relationship (compared with who were married), patients who were working or seeking work (compared with who retired), patients with anogenital involvement, patients who experienced pruritus or pain, with symptoms as sunburn or koebner phenomenon, and patients who had spent more than 10,000RMB (vs. \<10,000 RMB) on treatment had more impaired QoL. Intriguingly, the presence of vitiligo on visible sites, such as face, neck, scalp was not associated with a poor dermatology-specific QoL, which was inconsistent with the previous studies. Several studies showed that patients had higher scores of QoL when having lesions on visible sites\[[@pone.0210581.ref022],[@pone.0210581.ref023],[@pone.0210581.ref025],[@pone.0210581.ref026]\]. Nevertheless, there were also several studies did not find any relationship between DLQI score and visibility of lesions\[[@pone.0210581.ref006],[@pone.0210581.ref010],[@pone.0210581.ref027]\]. In our study, since most of participants had visible sites involvement (n = 829, 93.8%), the sample size of those without visible sites involvement may be too small (n = 55, 6.2%) to reach statistical significance. Meanwhile, all of our participants had been using camouflage for more than 1 month. QoL has been shown to be improved in vitiligo patients who had lesions on visible sites after use of camouflage\[[@pone.0210581.ref003],[@pone.0210581.ref004]\]. Therefore, we supposed that the effectiveness of hiding the visible vitiligo lesions might have abrogated the impact on the patient's QoL.

We found that the patients with lesions on hands had poor QoL (p = 0.052). These might be explained by the fact that acral lesions of vitiligo were usually resistant to conventional treatment\[[@pone.0210581.ref028]--[@pone.0210581.ref030]\] as well as surgical interventions\[[@pone.0210581.ref031]\], and the effect of camouflage on these visible sites could not sustain for long because of frequent hand-washing.

Camouflage use and QoL in vitiligo patients {#sec023}
-------------------------------------------

Our result showed a less QoL impairment than that reported by Wang et al.\[[@pone.0210581.ref022]\], who reported a mean total DLQI score of 8.40 in 101 Chinses vitiligo patients. This may be due to the difference between the target populations of these two studies, as we recruited the patients who had been using camouflage for at least one month, from the community, while in the previous study, dermatology clinic outpatients were enrolled.

There were 67 patients who finished the questionnaire were excluded from our primary analysis, as they used camouflage for less than one month. The mean DLQI score of them was higher than those who had been using camouflage for at least one month (7.22±6.83vs. 5.83±5.75), although the differences between the two groups did not reach statistically significance. One possible reason for the difference might be that continuous camouflage application improved the QoL of vitiligo patients who had lesions on visible sites\[[@pone.0210581.ref003],[@pone.0210581.ref004]\]. As another evidence, in our multivariate analysis, the degree of satisfaction after camouflage therapy was positively correlated with QoL of the patients.

Several limitations in our study should be addressed. Firstly, it was an online survey, thus the clinical characteristics such as type of vitiligo, disease activity, and vitiligo extent were unable to be assessed clinically. Secondly, there might be some non-serious respondents participated in the survey, and therefore would increase noise and reduce experimental power of the study\[[@pone.0210581.ref032]\]. For this reason, we performed a consistency and plausibility check to make sure most of the low-quality data sets submitted by non-serious respondents were excluded from the final analysis\[[@pone.0210581.ref032],[@pone.0210581.ref033]\]. Thirdly, although China and India shared many similarities in culture and belief, we found that some items in VIS-22 may not be suitable for our patients, further modification and validation is needed. Furthermore, family history was not assessed and should be considered in future studies.

Despite these limitations, our study demonstrated that vitiligo has considerable impact on QoL of affected patients in Chinese population even when they had been using camouflage for at least one month, and camouflage might be helpful to improve QoL of the patients.
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